Transaction · 0001209191-24-000801

Ticho Barry

Ticho Barry, CMO, reported an open-market or private sale at Stoke Therapeutics, Inc. involving 10000.000000 shares for an estimated $57352.00. Reported holdings after the transaction were 16981.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCMO
STOKStoke Therapeutics, Inc.
Filing timeJan 04
Trade dateJan 02, 2024
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

STOK price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
STOK since 2024-01-04Filed 974 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001209191-24-000801
Common Stock
Transaction date
Jan 02, 2024
Filed Jan 04, 2024, 04:38 PM · 2d delay
Shares
10.0k sh
$574 per share
Estimated value
-$5.73M
Computed from shares × price
Holdings after
16.9k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Holdings Reduction 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Medical Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The sale reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the reporting person.

  2. F2

    The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.15 to $5.97 per share, inclusive. The reporting person undertakes…

  3. F3

    The reported total includes an additional 1,086 shares of the issuer's stock that were acquired by the reporting person through the issuer's employee stock purchase plan in exempt transactions pursuan…

Original filing · 0001209191-24-000801
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

STOK